The Phase 1 stack is intentionally simple: two compounds, one injection, one nasal spray, both running nightly with a fixed cycle structure. That simplicity is the point. The corpus is unambiguous on this — when you're rebuilding a broken sleep architecture, the worst thing you can do is layer four compounds simultaneously and lose the ability to attribute what's actually working. Phase 1 is a 28-day diagnostic and therapeutic window: DSIP rebuilds delta-wave density while Selank flattens the daytime sympathetic spike that's been pulling cortisol forward into your evening. By Day 28 you'll know which of those two levers your nervous system was actually starved of — and that determines whether Phase 2 layers on the GH axis or pivots to a different rebuild.
What's actually happening in Weeks 1-4
DSIP is a nonapeptide that crosses the blood-brain barrier and modulates GABAergic tone in a way structurally distinct from benzodiazepines or Z-drugs — it doesn't bottleneck the GABA-A receptor and doesn't suppress REM. The practitioner corpus is explicit on the mechanism: DSIP shifts sleep architecture toward deeper delta waves (slow-wave Stage 3/4), the exact stage where glymphatic clearance runs, where memory consolidation happens, and where the nocturnal GH pulse fires. The corpus also flags the trade-off honestly: in some users deep sleep climbs to ~30% of total sleep time, and if that gain comes at the cost of REM dropping below baseline, you've over-corrected. That's why the tracking layer in this chapter is non-negotiable — you need to know your REM:deep ratio is moving the right direction, not just your total deep-sleep minutes.
Selank is doing different work on a different timescale. It's a heptapeptide analog of the endogenous tetrapeptide tuftsin, administered intranasally for direct nose-to-brain transport that bypasses first-pass metabolism. Mechanism: enkephalin-degrading enzyme inhibition, BDNF upregulation, and serotonergic/dopaminergic modulation that produces anxiolysis without sedation, cognitive impairment, or addiction potential. In a cortisol-axis context, this matters because most of the people running this Path aren't waking up at 3am from a sleep-pressure problem — they're waking up because their sympathetic tone never fully drops at sleep onset. Selank during the day lowers that baseline sympathetic charge so DSIP at night has less work to do. The two compounds are not redundant; they're sequential levers on the same axis.
The fourth week is the critical inflection point. By Day 21-28 you've accumulated enough nights of improved delta-wave density that the downstream effects start showing up in morning markers — salivary cortisol-awakening-response should be measurably steeper, HRV trend should be tracking up, and the subjective "wired but tired" pattern should be breaking. If it isn't, Phase 1 isn't broken — the upstream lever you identified in Chapter 2 is. That's the adjustment trigger, not "add more peptide."
The Phase 1 protocol
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| DSIP | 100–300 mcg | Subcutaneous | Nightly, ~60 min before bed | 🟢 Expert | Start at 100 mcg for nights 1–3 to assess; titrate to 200 mcg by week 2 if delta-wave response is muted. Cap at 300 mcg. |
| Selank | 200–400 mcg | Intranasal | 1–2x/day | 🟢 Expert | 30 days on / 10 off cycle. Morning dose mandatory; second dose pre-stressor or mid-afternoon if cortisol curve is inverted. |
The substrate is consistent: DSIP runs nightly through the full 28 days with no off-week inside Phase 1 — the receptor system doesn't downregulate the way GH secretagogues do, and the practitioner consensus describes architecture improvements building cumulatively across the first 14 nights. Selank follows the standard nasal-peptide cycling structure (30 on / 10 off) and the corpus is explicit that the cycling is for receptor reset, not toxicity — meaning if you hit Day 30 mid-Path, you take the 10-day off-window and DSIP continues solo. That solo-DSIP stretch is actually informative: it isolates which compound was carrying which effect.
Daily rhythm — what the 28 days actually look like
Morning (within 30 min of waking): Selank 200–400 mcg, single nostril, head tilted slightly back, no sniffing afterward. The practitioner corpus is specific on technique — alternate nostrils between doses, breathe in slowly to draw the spray onto the olfactory epithelium rather than down the throat. If you swallow the post-drip, you've wasted the dose.
Afternoon (optional, days you need it): Second Selank dose, 200 mcg, ideally 30–60 minutes before a known sympathetic trigger (afternoon meeting, training session, social demand). The corpus describes Selank as having a 4–6 hour functional window, so an afternoon dose should not bleed into bedtime.
Evening (~60 min before bed): DSIP subcutaneous injection. Reconstitute 5 mg vial in 2.5 mL bacteriostatic water → 2 mg/mL → 0.05 mL = 100 mcg, 0.10 mL = 200 mcg, 0.15 mL = 300 mcg. Inject into abdominal subcutaneous tissue, rotate sites nightly across a 4-quadrant pattern. The corpus flags that DSIP onset is fast (within 90 min) so timing matters — too early and you'll feel sedated before you're in bed; too late and you've shortened the runway.
Throughout the 28 days: wearable sleep tracking is mandatory, not optional. The practitioner corpus is explicit that the inputs that matter are deep-sleep minutes, REM minutes, REM:deep ratio, and resting HR overnight. Track all four nightly. Don't trust subjective sleep quality alone — DSIP can produce a "felt great" subjective response while your REM is collapsing, and that's the exact failure mode you need to catch by Day 14.
What you should feel
- Nights 1–3: Onset of DSIP effect is fast — the corpus describes "effects begin night 1–3." Expect deeper sleep latency drop and a subjective sense of waking less. Vivid dreams are common in the first week as REM rebounds from chronic suppression. Vivid is fine; nightmare is a dose-too-high signal — drop back to 100 mcg.
- Week 2 (Days 7–14): Measurable architecture shift on wearable — deep-sleep minutes climbing toward 90+ from baseline, REM holding or climbing. Selank's daytime effect should be obvious by now — flatter affect under normal stressors, less reactive evening cortisol spike.
- Week 3 (Days 14–21): Morning HRV trend up. The 3am wake pattern, if it was present, should be breaking. Subjective energy at 3pm — historically the cortisol-curve crash zone — should be cleaner.
- Week 4 (Days 21–28): Cortisol-awakening-response is now measurable on salivary repeat. This is the lab inflection point.
What's NOT happening yet
- GH axis is not optimized. DSIP nudges the nocturnal GH pulse via deep-sleep restoration, but you're not on a secretagogue stack yet. IGF-1 should not be expected to move in Phase 1. That's Phase 2.
- Full DUTCH cortisol curve hasn't remodeled. Salivary CAR moves fast (4–6 weeks); full diurnal curve and cortisol metabolite ratios take the full 12-week protocol. Don't re-pull DUTCH at Day 28 expecting a clean reset.
- TPO/TGA antibodies are not addressing. If your baseline flagged Hashimoto's, the Sleep/Cortisol Path isn't the lever for that — and Phase 1 won't pretend to be.
- Selank is not a stimulant. If you're expecting a Modafinil-shaped cognitive lift, you've miscalibrated. The lift is removal of the anxious-vigilance ceiling, not added drive. Different mechanism, different felt experience.
- Tolerance is not a concern at these doses. The corpus is explicit — DSIP doesn't downregulate at the 100–300 mcg range across 4 weeks, and Selank's 30-on/10-off structure is for receptor reset, not because effect is fading.
Architecture rebuilds on the timescale the substrate describes. Track the four numbers. Adjust.